TOKYO, Dec 13 (Reuters) - Eisai , opens new tab said on Wednesday its Alzheimer's drug Leqembi will launch in Japan on Dec. 20 following its inclusion on the National Health Insurance price list.

TOKYO, March 7 (Reuters) - Japanese drugmaker Eisai , opens new tab on Thursday said the distribution of its Alzheimer's drug Leqembi in the United States has proceeded slower than it expected.

TOKYO, Jan 18, 2024--- Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation ...

TOKYO, Nov 29 (Reuters) - Shares in Japanese drugmaker Eisai Co headed for their biggest plunge in more than a year on Tuesday after a report that a woman in a trial of the company's Alzheimer's ...

More and more pharma companies are looking "beyond the pill" when it comes to providing care for patients, few more so than Eisai, which is developing a package of products and services in Japan ...

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies. Skip to main content.

Eisai Co.’s new global ... US approval was really high and it was the main stage until now,” Naito said in a post-earnings briefing held in Tokyo ... other regions such as Japan, ...

TOKYO -- Japanese pharmaceutical company Eisai is developing an Alzheimer's disease treatment that targets a protein linked to symptoms, aiming to release it in the U.S. by fiscal 2030, Nikkei has ...

TOKYO, Dec 13 (Reuters) - Eisai said on Wednesday its Alzheimer's drug Leqembi will launch in Japan on Dec. 20 following its inclusion on the National Health Insurance price list. Intravenous ...

TOKYO – Japan's health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies.